Faldaprevir combined with peginterferon alfa-2a and ribavirin in chronic hepatitis C virus genotype-1 patients with prior nonresponse: SILEN-C2 trial

Hepatology

Volumn 57, Issue 6, 2013, Pages 2155-2163

  Sulkowski, Mark S ^a   Bourlière, Marc ^b   Bronowicki, Jean Pierre ^c   Asselah, Tarik ^d   Pawlotsky, Jean Michel ^e   Shafran, Stephen D ^f   Pol, Stanislas ^g   Mauss, Stefan ^h   Larrey, Dominique ⁱ   Datsenko, Yakov ^j   Stern, Jerry O ^k   Kukolj, George ^l   Scherer, Joseph ^k   Nehmiz, Gerhard ^j   Steinmann, Gerhard G ^j   Böcher, Wulf O ^j  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b HÔPITAL SAINT JOSEPH   (France)

^c UNIVERSITY HOSPITAL OF NANCY   (France)

^d BEAUJON HOSPITAL   (France)

^e HENRI MONDOR HOSPITAL   (France)

^f UNIVERSITY OF ALBERTA   (Canada)

^g UNIVERSITÉ PARIS DESCARTES   (France)

^h Center for HIV and Hepatogastroenterology   (Germany)

ⁱ HÔPITAL SAINT ELOI   (France)

^j BOEHRINGER INGELHEIM PHARMA GMBH AND CO KG   (Germany)

^k BOEHRINGER INGELHEIM PHARMACEUTICALS INC   (United States)

^l Boehringer Ingelheim Laval ^*  (Canada)

more..

Author keywords

[No Author keywords available]

Indexed keywords

FALDAPREVIR; PEGINTERFERON ALPHA2A; PLACEBO; RIBAVIRIN;

ADULT; ANEMIA; ANTIVIRAL THERAPY; ARTICLE; ASTHENIA; CONTROLLED STUDY; DECREASED APPETITE; DIARRHEA; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; DRY SKIN; FATIGUE; FEMALE; FEVER; FOLLOW UP; HEADACHE; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; INSOMNIA; JAUNDICE; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; MYALGIA; NAUSEA; OUTCOME ASSESSMENT; PHOTOSENSITIVITY DISORDER; PRIORITY JOURNAL; PRURITUS; RANDOMIZED CONTROLLED TRIAL; RASH; SIDE EFFECT; TREATMENT DURATION; TREATMENT RESPONSE; VIRUS LOAD; VOMITING;

ADULT; ANTIVIRAL AGENTS; CARRIER PROTEINS; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; FEMALE; GENOTYPE; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; INTERFERON-ALPHA; MALE; MIDDLE AGED; POLYETHYLENE GLYCOLS; RECOMBINANT PROTEINS; RIBAVIRIN; TREATMENT FAILURE; VIRAL NONSTRUCTURAL PROTEINS;

EID: 84878980518     PISSN: 02709139     EISSN: 15273350     Source Type: Journal    
DOI: 10.1002/hep.26386     Document Type: Article

References (15)

1. Yoshida EM, Sherman M, Bain VG, Cooper CL, Deschênes M, Marotta PJ, et al. Re-treatment with peginterferon alfa-2a and ribavirin in patients with chronic hepatitis C who have relapsed or not responded to a first course of pegylated interferon-based therapy. Can J Gastroenterol 2009; 23: 180-184.
2. Jensen DM, Marcellin P, Freilich B, Andreone P, Di Bisceglie A, Brandão-Mello CE, et al. Re-treatment of patients with chronic hepatitis C who do not respond to peginterferon-alpha2b: a randomized trial. Ann Intern Med 2009; 150: 528-540.
3. Bacon BR, Gordon SC, Lawitz E, Marcellin P, Vierling JM, Zeuzem S, et al. Boceprevir for previously treated chronic HCV genotype 1 infection. N Engl J Med 2011; 364: 1207-1217.
4. Zeuzem S, Andreone P, Pol S, Lawitz E, Diago M, Roberts S, et al. Telaprevir for retreatment of HCV infection. N Engl J Med 2011; 364: 2417-2428.
5. Yong C-L, Scherer J, Sabo J, Stern JO, Steinmann G, Bücher W. BI 201335 pharmacokinetics and early effect on viral load in HCV genotype-1 patients [Abstract 1249]. J Hepatol 2011; 54(Suppl 1):S493.
6. Manns MP, Bourlière M, Benhamou Y, Pol S, Bonacini M, Trepo C, et al. Potency, safety and pharmacokinetics of the NS3/4A protease inhibitor BI201335 in patients with chronic HCV genotype-1 infection. J Hepatol 2011; 54: 1114-1122.
7. Sulkowski MS, Asselah T, Lalezari J, Ferenci P, Fainboim H, Leggett B, et al. Faldaprevir combined with peginterferon alfa-2a and ribavirin in treatment-naïve patients with chronic genotype-1 HCV: SILEN-C1 trial. Hepatol 2013. doi: 10.1002/hep.26276. [Epub ahead of print].
8. Neumann AU, Lam NP, Dahari H, Gretch DR, Wiley TE, Layden TJ, et al. Hepatitis C viral dynamics in vivo and the antiviral efficacy of interferon-alpha therapy. Science 1998; 282: 103-107.
9. Chevaliez S, Bouvier-Alias M, Brillet R, Pawlotsky JM. Hepatitis C virus (HCV) genotype 1 subtype identification in new HCV drug development and future clinical practice. PLoS One 2009; 4: e8209.
10. McHutchison JG, Lawitz EJ, Shiffman ML, Muir AJ, Galler GW, McCone J, et al. Peginterferon alfa-2b or alfa-2a with ribavirin for treatment of hepatitis C infection. N Engl J Med 2009; 361: 580-593.
11. Zeuzem S, Berg T, Gane E, Ferenci P, Foster GR, Fried MW, et al. TMC435 in HCV genotype 1 patients who have failed previous pegylated interferon/ribavirin treatment: final SVR24 results of the ASPIRE trial [Abstract 2]. J Hepatol 2012; 56(Suppl 1):S1-S2.
12. Ghany MG, Nelson DR, Strader DB, Thomas DL, Seeff LB; American Association for Study of Liver Diseases. An update on treatment of genotype 1 chronic hepatitis C virus infection: 2011 practice guideline by the American Association for the Study of Liver Diseases. Hepatology 2011; 54: 1433-1444.
13. Sarrazin C, Kieffer TL, Bartels D, Hanzelka B, Müh U, Welker M, et al. Dynamic hepatitis C virus genotypic and phenotypic changes in patients treated with the protease inhibitor telaprevir. Gastroenterology 2007; 132: 1767-1777.
14. Huisman MT, Snoeys J, Monbaliu J, Martens M, Sekar V, Raoof A. In vitro studies investigating the mechanism of interaction between TMC435 and hepatic transporters [Abstract 278]. Hepatology 2010; 52(Suppl 1):S461A.
15. Sane R, Podila L, Mathur A, Mease K, Taub M, Huang Q, et al. Mechanisms of isolated unconjugated hyperbilirubinaemia induced by the HCV NS3/4A protease inhibitor BI 201335 [Abstract 1236]. J Hepatol 2011; 54(Suppl 1):S488.